Bristol Myers Squibb (BMS) has entered into two separate research collaboration and license agreements with SyntheX and Autolus Therapeutics to expand its protein degradation and cell therapy portfolios. The former deal involves BMS committing an undisclosed upfront payment as well as up to US$550 M in milestone payments to develop molecular glue-based protein degraders using SyntheX’s ToRNeDO platform. Additionally, BMS is also investing in Autolus’ RQR8 safety switch for use in cell therapy programmes for the treatment of cancer.